Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03408652
Other study ID # MOSCAR
Secondary ID 2017-004075-31
Status Terminated
Phase Phase 3
First received
Last updated
Start date March 15, 2019
Est. completion date June 22, 2020

Study information

Verified date October 2021
Source Centre Leon Berard
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter, randomized, open-label, 2-arm, parallel-group, phase III study whose goal is to assess the efficacy and safety profile of bone-targeted treatments (Arm A: denosumab or zoledronic acid) versus the control arm (Arm B: no specific treatment) in patients with bone metastases under targeted therapy for Metastatic Renal Cell Carcinoma.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date June 22, 2020
Est. primary completion date June 22, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years. - Histologically proven mRCC. - Administration of one of the systemic agents in use for the treatment of mRCC (no more than three prior systemic therapy regimens). Patients with at least 6 months of 1st line treatment and a bone event may be included. - More than 1 bone metastasis. - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2. - Adequate renal function (serum creatinine = 200 mmol/L or creatinine clearance = 30 mL/min according to Cockroft formula or MDRD formula for patients older than 65 years). - Covered by a medical insurance. - Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. - Signed informed consent. - Accepting to use effective contraception during study treatment and within 5 months after final dose of study therapy. Exclusion Criteria: - Prior bisphosphonate or denosumab treatment in the year before inclusion. - Imminent or ongoing nerve or spinal compression as per the investigator's judgement. - Ongoing first-line therapy, started for less than 6 months (patients with BM at time of metastases diagnosis will initially benefit from the angiogenesis targeted agents used and are not at higher risk). - Anticancer treatment under investigation. - Paraneoplastic hypercalcemia (corrected total calcium > 2.7 mmol/L). - Grade 4 toxicity under previous targeted agents. - Liver failure (AST and/or ALT = 5.0 x upper limit of normal (ULN) or total bilirubin beyond normal limits). - Severe hypocalcaemia > 2.8 mmol/l. - Fructose intolerance. - Invasive dental procedure (i.e. tooth extraction, dental implants, oral surgery) within the 10 days prior to randomization or required dental procedures at the pre-inclusion dental examination. - Psychological, familial, sociological, geographical conditions that would limit compliance with study protocol requirements. - Pregnant or breastfeeding woman. Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior inclusion. - Life expectancy = 3 months. - Participation to another clinical trial that might interfere with the evaluation of the main criterion. - Known hypersensitivity to the active substance or to any of the excipients of bisphosphonate or denosumab.

Study Design


Intervention

Drug:
denosumab
Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.

Locations

Country Name City State
France Centre Leon Berard Lyon

Sponsors (1)

Lead Sponsor Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to first Skeletal Related Event Defined as the time from randomization to first SRE. Patients without event will be censored at the time of the last clinical evaluation. Up to 54 months after the first inclusion
Secondary Number of specific event-free survivals Specific times from randomization to appearance of the first Skeletal Related Event. Up to 54 months after the first inclusion
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Incidence of adverse events (AEs) assessed using the National Cancer Institute - Common Terminology Criteria for Adverse Event (NCI-CTCAE) v4 grading scale, specific registration of ONJ or other osteonecrosis and rate of skeletal event per patient during study duration Every 3 months until the 18th month for each patient
Secondary Evolution of pain severity Proportion of patients with a clinically meaningful change in pain severity evaluated using a numerical rating scale (NRS) Every 3 months until the 18th month for each patient
Secondary Evolution of pain Proportion of patients that shifted from not taking a strong opioid at baseline Every 3 months until the 18th month for each patient
Secondary Patient's condition evaluation "Functional Assessment of cancer Therapy-General (FACT-G)" questionnaire, made of 27 items measuring the respondents' health state, each of which is answered using a five-point scale from 0 (not at all) to 4 (very much). Questions are phrased so that higher numbers indicate a better health state. Subscale scores are added to obtain total score. Up to 9 months for each patient (evaluated at baseline, months 3, 6, 9)
Secondary Patient's condition evaluation "EuroQoL 5 Dimensions 5 Levels" questionnaire is a scale used in the health state description. Each items is a three-level scale : having no problems, having some or moderate problems, being unable to do/having extreme problems.The respondents are asked to choose one of the statements which best describes their health status of surveyed day. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions). Up to 18 months for each patient (evaluated at baseline, months 3, 6, 9 and 18)
Secondary Overall survival Measured from the date of randomization to the date of death from any cause Up to 54 months after the first inclusion
Secondary Evaluation of the different practices for bone metastases treatments Financial evaluation of centers' practices (home or hospitalization) Up to 18 months for each patient
Secondary Cost-utility analysis All the hospitalization costs will be collected during the timeframe: outpatient, inpatient, and home care Up to 18 months for each patient
Secondary Cost-effectiveness analyses All the hospitalization costs will be collected during the timeframe: outpatient, inpatient, and home care Up to 18 months for each patient
Secondary Budget impact analysis Quantification of financial consequences of rolling out this kind of medical supportive care strategy throughout the health system. Up to 18 months for each patient
See also
  Status Clinical Trial Phase
Completed NCT00930033 - Clinical Trial to Assess the Importance of Nephrectomy Phase 3
Recruiting NCT05863351 - Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study Phase 3
Not yet recruiting NCT06284564 - A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) Phase 2
Completed NCT00414765 - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Phase 4
Active, not recruiting NCT03149822 - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Phase 1/Phase 2
Recruiting NCT03647878 - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed NCT01517243 - Phase II Study of Alternating Sunitinib and Temsirolimus Phase 2
Withdrawn NCT03927248 - PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT02122003 - Second Line Sorafenib After Pazopanib in Patients With RCC Phase 2
Completed NCT01182142 - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients Phase 2
Completed NCT00630409 - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Completed NCT04076787 - Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Active, not recruiting NCT04467021 - Cancer and Blood Pressure Management, CARISMA Study N/A
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT02282579 - Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
Terminated NCT02071641 - Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma Phase 2
Completed NCT01731158 - Sequential Therapy in Metastatic Renal Cell Carinoma Phase 2
Terminated NCT01342627 - Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma Phase 2
Active, not recruiting NCT01274273 - Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer Phase 2